atezolizumab,nivolumab,cabozantinib,tivozanib
roche,aveo oncology,bms
['nivo', 'atezo', 'tinivo2', 'rcc,(-irccs),(-srcc),(-urcc)', 'contact03', 'cabozantinib']
re-challenging immunotherapy after progression in mrcc? contact03: ph3 trial of atezolizumab(pdl1) + cabozantinib vs cabozantinib alone in post-io mrcc: no benefit in os role of rechallenge of pd1, pending tinivo2 trial #asco23 
Medical oncologist @GACancerCenter, Augusta University specializing in genitourinary &breast oncology. Editor and TB moderator @themednet.org #patientadvocate